Panlong Pharmaceutical released its 2026 interim report. Net profit attributable to the parent in the first half was 42.38 million yuan, down 29.5% year on year. Operating revenue was 423 million yuan, down 26.4% year on year. Net profit attributable to the parent after deducting non-recurring items was 38.49 million yuan, down 27.2% year on year. Net operating cash flow was 177 million yuan, up 181.9% year on year. Earnings per share were 0.31 yuan. In the second quarter, operating revenue was 200 million yuan, down 38.2% year on year, and net profit attributable to the parent was 20.62 million yuan, down 28.6% year on year. As of the end of the second quarter, total assets were 2.347 billion yuan, up 1.03% from the end of the previous year, and net assets attributable to the parent were 1.735 billion yuan, up 2.9% from the end of the previous year. The company said there were no major changes in its business during the reporting period. It continued to focus on pharmaceutical manufacturing as its core, with a product lineup led by Panlongqi Tablets and covering multiple functional categories.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class AFirst-half net profit attributable to parent fell 29.5% to 42.38 million yuan, with revenue down 26.4%.
